What is APTOSE BIOSCIENCES INC's earnings per share (EPS)?

APTOSE BIOSCIENCES INC (APTOF) reported diluted earnings per share of -$10.41 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

APTOSE BIOSCIENCES INC (APTOF) Financials

APTOF

FY2025 annual

Revenue $0 YoY not available

Net Income -$25.5M -0.1% YoY

EPS (Diluted) -$10.41 YoY not available

Free Cash Flow -$22.0M +38.9% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the APTOF SEC filings page.

APTOSE BIOSCIENCES INC (APTOF) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI APTOF FY2025 2026-08-29

An R&D-led business remains funded by external capital while operating losses convert almost directly into cash outflows.

In FY2025, operating cash flow of -$22.0M was close to net loss of -$25.5M, indicating that losses translated into cash use rather than being dominated by noncash items. That pattern also held in FY2024, making cash conversion—not merely reported profitability—the central operating constraint.

Liabilities rose from $14.7M in FY2024 to $37.2M in FY2025, leaving obligations larger than total assets. Negative equity reached -$27.2M and the current ratio fell to 0.7x, showing simultaneous long-term balance-sheet erosion and short-term tightness.

Financing provided $19.4M in FY2025 against operating cash outflow of $22.0M, so external capital nearly offset—but did not exceed—core cash consumption. The reported liquidity comparison was just 0.5 months of the latest annual operating outflow, indicating limited resources relative to that spending pace.

Financial Health Signals

Financial health score not available

APTOSE BIOSCIENCES INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/7

APTOSE BIOSCIENCES INC passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

APTOSE BIOSCIENCES INC reported a net loss of $25.5M while operations used $22.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

APTOSE BIOSCIENCES INC generated $0 in revenue in Q1 2026.

Net Income

-$7.6M

YoY-37.7%

APTOSE BIOSCIENCES INC reported -$7.6M in net income in Q1 2026. This represents a decrease of 37.7% from the same quarter a year earlier.

EPS (Diluted)

-$2.99

YoY-14.6%

QoQ+2.6%

APTOSE BIOSCIENCES INC earned -$2.99 per diluted share (EPS) in Q1 2026. This represents a decrease of 14.6% from the same quarter a year earlier. Against the prior quarter it is up 2.6%.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$4.1M

YoY-13.6%

QoQ+338.5%

5Y CAGR-45.7%

APTOSE BIOSCIENCES INC held $4.1M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY0.0%

QoQ0.0%

5Y CAGR-50.8%

APTOSE BIOSCIENCES INC had 3M shares outstanding in Q1 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

None of these metrics is reported for Q1 2026.

Capital Allocation

R&D Spending

$3.6M

YoY+53.2%

APTOSE BIOSCIENCES INC invested $3.6M in research and development in Q1 2026. This represents an increase of 53.2% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

APTOF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

APTOF quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Revenue	N/A	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A
R&D Expenses	N/A	$11.3M-24.9%	$15.1M-54.6%	$33.3M+35.6%	$24.5M-46.7%	$46.0M+57.0%	$29.3M+74.0%	$16.8M-10.1%	$18.7M+198.6%	$6.3M
SG&A Expenses	N/A	$13.4M+20.0%	$11.2M-28.5%	$15.6M+7.4%	$14.5M-25.4%	$19.5M-26.5%	$26.5M+164.2%	$10.0M-3.4%	$10.4M+86.9%	$5.6M
Income Tax	N/A	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$25.5M-0.1%	-$25.4M+50.3%	-$51.2M-22.4%	-$41.8M+36.0%	-$65.4M-18.3%	-$55.2M-110.2%	-$26.3M+9.0%	-$28.9M-147.9%	-$11.6M
EPS (Basic)	N/A	-$10.41+71.4%	-$36.38+84.0%	-$227.43-3244.6%	-$6.80-831.5%	-$0.73	N/A	N/A	N/A	N/A
EPS (Diluted)	-$10.83	-$10.41	-$36.38	-$227.43	-$6.80	-$0.73	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	2M	698,980	225,154	6M	89,086	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$0	N/A	$0	$0	$0	N/A	$0	$0
R&D Expenses	$3.6M+53.2%	N/A	$2.2M-53.1%	$3.3M-25.3%	$2.4M-63.3%	N/A	$4.7M-43.0%	$4.4M-58.3%
SG&A Expenses	$3.6M+15.0%	N/A	$2.7M+19.7%	$3.6M+23.6%	$3.1M-6.6%	N/A	$2.3M-33.9%	$2.9M-24.2%
Interest Expense	N/A	N/A	-$212K-1866.7%	-$110K-218.3%	-$84K-169.4%	N/A	$12K	$93K
Net Income	-$7.6M-37.7%	N/A	-$5.1M+26.3%	-$7.0M+2.9%	-$5.5M+42.5%	N/A	-$7.0M+39.3%	-$7.3M+48.7%
EPS (Basic)	-$2.99-14.6%	-$3.07+91.2%	-$2.01+82.3%	-$2.76+78.8%	-$2.61+88.1%	-$34.90-2122.9%	-$11.33-543.8%	-$12.99-472.2%
EPS (Diluted)	-$2.99-14.6%	-$3.07+91.2%	-$2.01	-$2.76	-$2.61	-$34.90	-$11.33	-$12.99
Diluted Shares (Avg)	3M+20.0%	N/A	3M	3M	2M	N/A	613,604	558,476

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Operating Income, EBITDA, Income Tax.

APTOF Balance Sheet

APTOF quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Total Assets	$10.0M-1.1%	$10.1M-22.0%	$13.0M-74.5%	$51.0M-38.2%	$82.5M-34.6%	$126.3M+25.7%	$100.5M+495.6%	$16.9M+41.0%	$12.0M
Current Assets	$6.4M-32.4%	$9.5M-19.9%	$11.9M-76.0%	$49.5M-39.4%	$81.7M-34.7%	$125.1M+26.6%	$98.8M+499.1%	$16.5M+39.4%	$11.8M
Cash & Equivalents	$935K-84.8%	$6.2M-33.5%	$9.3M-75.0%	$37.0M-5.5%	$39.1M-66.7%	$117.4M+47.0%	$79.8M+421.9%	$15.3M+43.9%	$10.6M
Short-Term Investments	$0	$0	$0-100.0%	$10.0M-75.0%	$40.0M+700.3%	$5.0M-71.8%	$17.8M+3935.9%	$440K-44.9%	$798K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$37.2M+153.4%	$14.7M-7.7%	$15.9M+19.6%	$13.3M+60.3%	$8.3M+12.8%	$7.3M+12.2%	$6.5M+134.9%	$2.8M+58.0%	$1.8M
Current Liabilities	$9.3M+108.7%	$4.5M-70.8%	$15.3M+24.3%	$12.3M+50.3%	$8.2M+20.0%	$6.8M+23.0%	$5.5M+98.6%	$2.8M+58.0%	$1.8M
Non-Current Liabilities	$27.9M+173.0%	$10.2M+1544.3%	$621K-38.0%	$1.0M+771.3%	$115K-78.5%	$535K-47.1%	$1.0M	$0	$0
Total Equity	-$27.2M-498.0%	-$4.5M-56.6%	-$2.9M-107.7%	$37.7M-49.2%	$74.2M-37.6%	$118.9M+26.6%	$93.9M+567.0%	$14.1M+38.0%	$10.2M
Retained Earnings	-$566.4M-4.7%	-$541.0M-4.9%	-$515.5M-11.0%	-$464.3M-9.9%	-$422.5M-18.3%	-$357.2M-18.3%	-$301.9M-9.5%	-$275.6M-11.7%	-$246.8M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$10.7M+43.6%	$10.0M-1.1%	$6.3M-42.0%	$5.6M-48.9%	$7.5M-41.6%	$10.1M-22.0%	$10.9M-47.6%	$10.9M-58.8%
Current Assets	$6.2M-11.7%	$6.4M-32.4%	$3.8M-63.1%	$3.3M-67.8%	$7.0M-41.0%	$9.5M-19.9%	$10.2M-48.0%	$10.2M-59.8%
Cash & Equivalents	$4.1M-13.6%	$935K-84.8%	$613K-92.3%	$553K-93.4%	$4.7M-35.4%	$6.2M-33.5%	$8.0M-49.4%	$8.3M-0.8%
Short-Term Investments	$0	$0	$0	$0	$0-100.0%	$0	$0-100.0%	$0-100.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$45.4M+205.5%	$37.2M+153.4%	$25.8M+28.6%	$20.0M+52.1%	$14.9M+17.4%	$14.7M-7.7%	$20.1M+53.2%	$13.1M+2.6%
Current Liabilities	$11.2M+77.9%	$9.3M+108.7%	$7.1M-27.5%	$9.0M-29.2%	$6.3M-48.0%	$4.5M-70.8%	$9.8M-21.2%	$12.7M+6.2%
Non-Current Liabilities	$34.2M+299.9%	$27.9M+173.0%	$18.7M+81.6%	$11.0M+2547.8%	$8.5M+1542.7%	$10.2M+1544.3%	$10.3M+1331.3%	$414K-49.3%
Total Equity	-$34.7M-369.0%	-$27.2M-498.0%	-$19.4M-112.9%	-$14.4M-560.4%	-$7.4M-5496.4%	-$4.5M-56.6%	-$9.1M-217.5%	-$2.2M-115.8%
Retained Earnings	-$574.1M-5.0%	-$566.4M-4.7%	-$558.7M-3.6%	-$553.6M-4.0%	-$546.5M-4.1%	-$541.0M-4.9%	-$539.4M-7.1%	-$532.4M-8.2%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

APTOF Cash Flow Statement

APTOF quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Operating Cash Flow	-$25.0M	-$22.0M+38.9%	-$36.0M+19.3%	-$44.6M-38.0%	-$32.3M+25.4%	-$43.3M-27.8%	-$33.9M-57.2%	-$21.6M+7.1%	-$23.2M-127.0%	-$10.2M
Depreciation & Amortization	N/A	$22K-31.3%	$32K-63.6%	$88K-26.7%	$120K-20.0%	$150K-1.3%	$152K0.0%	$152K+74.7%	$87K+3.6%	$84K
Stock-Based Compensation	N/A	$477K-55.0%	$1.1M-71.0%	$3.7M-29.8%	$5.2M-59.8%	$12.9M-39.6%	$21.4M+833.7%	$2.3M-46.3%	$4.3M+423.4%	$817K
Capital Expenditures	N/A	$0-100.0%	$5K-82.8%	$29K+20.8%	$24K-88.7%	$212K+168.4%	$79K-22.5%	$102K-69.0%	$329K+2430.8%	$13K
Free Cash Flow	N/A	-$22.0M+38.9%	-$36.0M+19.4%	-$44.6M-37.9%	-$32.3M+25.7%	-$43.5M-28.1%	-$34.0M-56.8%	-$21.7M+8.0%	-$23.5M-129.9%	-$10.2M
Investing Cash Flow	$0	$0-100.0%	$18K-99.8%	$10.0M-66.9%	$30.1M+185.4%	-$35.2M-378.8%	$12.6M+172.7%	-$17.4M-144850.0%	$12K+101.5%	-$811K
Financing Cash Flow	$24.4M	$19.4M-42.0%	$33.4M+383.6%	$6.9M+5856.9%	$116K-48.7%	$226K-99.6%	$58.8M-43.2%	$103.4M+271.2%	$27.9M+103.2%	$13.7M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$5.8M-109.0%	-$5.8M+27.5%	-$7.4M+28.6%	-$5.9M-2.9%	-$2.8M+76.2%	-$8.1M+12.9%	-$10.4M+1.5%	-$5.8M+57.2%
Depreciation & Amortization	$2K-33.3%	$4K0.0%	$11K+175.0%	$4K-50.0%	$3K-81.3%	$4K-77.8%	$4K-80.0%	$8K-63.6%
Stock-Based Compensation	$129K-60.4%	N/A	$44K+438.5%	$64K-69.1%	$326K-59.7%	N/A	-$13K-102.2%	$207K-73.1%
Investing Cash Flow	$0	$0	$0	$0-100.0%	$0+100.0%	$0-100.0%	$0-100.0%	$2.0M+202.5%
Financing Cash Flow	$5.8M+605.7%	$8.3M+22.0%	$7.8M-22.6%	$2.5M-47.4%	$829K-93.0%	$6.8M+696.8%	$10.0M+104.2%	$4.8M+330.6%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

APTOF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

APTOF quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Return on Equity	N/A	N/A	N/A	-110.8%-22.8pp	-88.0%-41.6pp	-46.5%-18.5pp	-28.0%+177.0pp	-205.0%-90.9pp	-114.1%
Return on Assets	-254.4%-3.3pp	-251.1%+143.1pp	-394.2%-312.3pp	-82.0%-2.8pp	-79.2%-35.4pp	-43.8%-17.6pp	-26.2%+145.0pp	-171.1%-73.8pp	-97.3%
Current Ratio	0.69-1.4x	2.14+1.4x	0.78-3.3x	4.03-6.0x	10.00-8.4x	18.36+0.5x	17.83+11.9x	5.91-0.8x	6.70
Debt-to-Equity	N/A	N/A	N/A	0.35+0.2x	0.110.0x	0.060.0x	0.07-0.1x	0.200.0x	0.17
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Return on Assets	-71.2%+3.0pp	N/A	-80.8%-17.2pp	-126.0%-59.7pp	-74.2%+1.1pp	N/A	-63.6%-8.8pp	-66.2%-13.1pp
Current Ratio	0.55-0.6x	0.69-1.4x	0.53-0.5x	0.36-0.4x	1.10+0.1x	2.14+1.4x	1.05-0.5x	0.80-1.3x
Asset Turnover	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.

Note: Shareholder equity is negative (-$27.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.69), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
APTOSE BIOSCIENCES INC APTOF	FY2025	$0	-$25.5M	N/A	$4.3M	—
NASCENT BIOTECH INC NBIO	FY2024	N/A	-$2.1M	N/A	$3.3M	—
MOSAIC IMMUNOENGINEERING CPMV	FY2025	N/A	N/A	N/A	$442K	—
AVENUE THERAPEUTICS INC ATXI	FY2025	$1.4M	-$2.9M	N/A	$2.8M	—

Where APTOSE BIOSCIENCES INC Ranks

Frequently Asked Questions

What is APTOSE BIOSCIENCES INC's annual revenue?

APTOSE BIOSCIENCES INC (APTOF) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is APTOSE BIOSCIENCES INC profitable?

No, APTOSE BIOSCIENCES INC (APTOF) reported a net income of -$25.5M in fiscal year 2025.

What is APTOSE BIOSCIENCES INC's free cash flow?

APTOSE BIOSCIENCES INC (APTOF) recorded an outflow of $22.0M in free cash flow during fiscal year 2025. This represents a 38.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is APTOSE BIOSCIENCES INC's operating cash flow?

APTOSE BIOSCIENCES INC (APTOF) recorded an outflow of $22.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are APTOSE BIOSCIENCES INC's total assets?

APTOSE BIOSCIENCES INC (APTOF) had $10.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are APTOSE BIOSCIENCES INC's capital expenditures?

APTOSE BIOSCIENCES INC (APTOF) reported no capital expenditure during fiscal year 2025.

How much does APTOSE BIOSCIENCES INC spend on research and development?

APTOSE BIOSCIENCES INC (APTOF) invested $11.3M in research and development during fiscal year 2025.

How many shares does APTOSE BIOSCIENCES INC have outstanding?

APTOSE BIOSCIENCES INC (APTOF) had 3M shares outstanding as of fiscal year 2025.

What is APTOSE BIOSCIENCES INC's current ratio?

APTOSE BIOSCIENCES INC (APTOF) had a current ratio of 0.69 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is APTOSE BIOSCIENCES INC's return on assets (ROA)?

APTOSE BIOSCIENCES INC (APTOF) had a return on assets of -254.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does APTOSE BIOSCIENCES INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, APTOSE BIOSCIENCES INC (APTOF) held $935K in cash, cash equivalents and investments, and reported an operating cash outflow of $22.0M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is APTOSE BIOSCIENCES INC's debt-to-equity ratio negative or not reported?

APTOSE BIOSCIENCES INC (APTOF) has negative shareholder equity of -$27.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is APTOSE BIOSCIENCES INC's Piotroski F-Score?

APTOSE BIOSCIENCES INC (APTOF) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are APTOSE BIOSCIENCES INC's earnings high quality?

APTOSE BIOSCIENCES INC (APTOF) reported a net loss of $25.5M while operations used $22.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.